tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

VERV Stock Latest News

Promising Outlook for Verve Therapeutics: Buy Rating Backed by Innovative Treatments and Strategic Partnerships
RatingsPromising Outlook for Verve Therapeutics: Buy Rating Backed by Innovative Treatments and Strategic Partnerships
19h ago
VERV
Optimistic Outlook for Verve Therapeutics Amid Promising Developments and Strategic Partnerships
PremiumRatings
Optimistic Outlook for Verve Therapeutics Amid Promising Developments and Strategic Partnerships
22h ago
VERV
Buy Rating for Verve Therapeutics: VERVE-102’s Enhanced Safety and Promising Efficacy Boost Investor Confidence
PremiumRatings
Buy Rating for Verve Therapeutics: VERVE-102’s Enhanced Safety and Promising Efficacy Boost Investor Confidence
15d ago
VERV
Verve Therapeutics announces anticipated 2025 milestones
PremiumThe Fly
Verve Therapeutics announces anticipated 2025 milestones
1M ago
LLY
VERV
Verve Therapeutics sees cash runway into mid-2027
PremiumThe Fly
Verve Therapeutics sees cash runway into mid-2027
1M ago
VERV
Verve Therapeutics has positive read from NewAmsterdam data, says Stifel
PremiumThe FlyVerve Therapeutics has positive read from NewAmsterdam data, says Stifel
2M ago
NAMS
VERV
Verve Therapeutics price target lowered to $17 from $20 at RBC Capital
Premium
The Fly
Verve Therapeutics price target lowered to $17 from $20 at RBC Capital
4M ago
VERV
Verve Therapeutics price target raised to $32 from $29 at Canaccord
Premium
The Fly
Verve Therapeutics price target raised to $32 from $29 at Canaccord
4M ago
VERV
Verve Therapeutics price target lowered to $14 from $15 at H.C. Wainwright
PremiumThe Fly
Verve Therapeutics price target lowered to $14 from $15 at H.C. Wainwright
4M ago
VERV
Verve Therapeutics Reports Q3 Progress and Financials
PremiumCompany Announcements
Verve Therapeutics Reports Q3 Progress and Financials
4M ago
VERV
Verve Therapeutics reports Q3 EPS (59c), consensus (70c)
PremiumThe Fly
Verve Therapeutics reports Q3 EPS (59c), consensus (70c)
4M ago
VERV
Verve Therapeutics sees cash runway through 2026
PremiumThe Fly
Verve Therapeutics sees cash runway through 2026
4M ago
VERV
Verve Therapeutics, Inc. (VERV) Q3 Earnings Cheat Sheet
PremiumPre-EarningsVerve Therapeutics, Inc. (VERV) Q3 Earnings Cheat Sheet
4M ago
VERV
Verve Therapeutics’ (VERV) Gene-Editing Therapies Could Be a Game Changer
Premium
Market News
Verve Therapeutics’ (VERV) Gene-Editing Therapies Could Be a Game Changer
6M ago
VERV
Levi & Korsinsky LLP Notifies Shareholders of Verve Therapeutics, Inc.(VERV) of a Class Action Lawsuit and an Upcoming Deadline
Premium
Class Action
Levi & Korsinsky LLP Notifies Shareholders of Verve Therapeutics, Inc.(VERV) of a Class Action Lawsuit and an Upcoming Deadline
6M ago
VERV
Verve Therapeutics price target lowered to $29 from $30 at Canaccord
PremiumThe Fly
Verve Therapeutics price target lowered to $29 from $30 at Canaccord
6M ago
VERV
Verve Therapeutics reports Q2 EPS (59c), consensus (68c)
PremiumThe Fly
Verve Therapeutics reports Q2 EPS (59c), consensus (68c)
7M ago
VERV
Verve Therapeutics Expands Board with Two New Members
PremiumCompany Announcements
Verve Therapeutics Expands Board with Two New Members
8M ago
8K
VERV
Verve Therapeutics appoints Nia Tatsis, Jodie Morrison to board
PremiumThe Fly
Verve Therapeutics appoints Nia Tatsis, Jodie Morrison to board
8M ago
QTTB
VERV
Verve Therapeutics Announces New Chief Scientific Officer
PremiumCompany AnnouncementsVerve Therapeutics Announces New Chief Scientific Officer
9M ago
8K
VERV
Verve Therapeutics CSO Andrew Bellinger steps down, Troy Lister to succeed
Premium
The Fly
Verve Therapeutics CSO Andrew Bellinger steps down, Troy Lister to succeed
9M ago
VERV
Verve Therapeutics COO buys $475.8K in common stock
Premium
The Fly
Verve Therapeutics COO buys $475.8K in common stock
9M ago
VERV

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >